Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16816765 | 0.92 | PDE5A (1.00) | PDE5A | |
| SCHEMBL16816367 | 0.91 | PDE5A (1.00) | PDE5A | |
| SCHEMBL19158119 | 0.91 | PDE5A (0.84) | PDE5A | |
| SCHEMBL16816838 | 0.88 | PDE5A (1.00) | PDE5A | |
| SCHEMBL17013456 | 0.88 | PDE5A (0.79) | PDE5A | |
| SCHEMBL4988990 | 0.88 | PDE5A (0.82) | PDE5A | |
| SCHEMBL16816875 | 0.88 | PDE5A (1.00) | PDE5A | |
| Hydrochloric Acid SCHEMBL4987593 | 0.87 | PDE5A (0.81) | PDE5A | |
| SCHEMBL19158435 | 0.87 | PDE5A (0.76) | PDE5A | |
| SCHEMBL16816555 | 0.86 | PDE5A (0.89) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | PDE5A 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.